Adopting an orphan
نویسنده
چکیده
507 suggests that there must be some pathogens that affect both plants and animals. Indeed, one such example is the bacterium Pseudomonas aeruginosa, which attacks both Homo sapiens and Arabidopsis. Perhaps more significant are the common conditions that arise when the immune system malfunctions. There are many known autoimmune diseases in humans, but plants also suffer from them. In lesion mimics, the hypersensitive response that triggers cell death is initiated in the absence of a pathogen. In extreme cases, the whole plant dies from multiple lesions, although this is not a major problem for horticulture or agriculture. The exact mechanisms involved are still unknown, but there is common ground for plant and animal immunologists to study the pathways involved in autoimmune disease, especially where PCD is concerned. Much work still remains to elucidate the immune response in detail, particularly the steps after the pathogen is detected. Nevertheless, cooperation between plant and animal researchers has already yielded important insights into these mechanisms. It is becoming increasingly clear that these two communities, who for so long communicated so little, can pool their resources to investigate immunity.
منابع مشابه
The Issue of 'Orphan' Works in Digital Libraries, Especially as Treated by the Directive 2012/28
This paper analyzes the 'orphan' works problem of the digital libraries' perspective. 'Orphan' works, i.e. works of an unidentified-or unlocated-author, create a legal uncertainty, mostly affecting the large scale users in their mass digitization projects, that, although they need to use the works and they are willing to obtain a license, they are unable to do so, since they do not know from wh...
متن کاملAdopting orphan drugs--two dozen years of treating rare diseases.
445 ing or evaluating the work of so many volunteers. Some organizations conduct internal evaluations, and they tend to agree with experienced volunteers on some guidelines for effective overseas missions. It is best, they say, to send an advance team so that requirements such as lodging, an adequate electrical supply, clinic space, and surgical facilities can be anticipated. Many stress the im...
متن کاملFunding innovation for treatment for rare diseases: adopting a cost-based yardstick approach
BACKGROUND Manufacturers justify the high prices for orphan drugs on the basis that the associated R&D costs must be spread over few patients. The proliferation of these drugs in the last three decades, combined with high prices commonly in excess of $100,000 per patient per year are placing a substantial strain on the budgets of drug plans in many countries. Do insurers spend a growing portion...
متن کاملInsurance companies' perspectives on the orphan drug pipeline.
BACKGROUND Rare diseases are of increasing concern to private and public healthcare insurance plans. Largely neglected by manufacturers before the 1983 passing of the Orphan Drug Act (ODA), orphan drugs have become a commercialization target of steadily increasing importance to the healthcare industry. The ODA mandates the coverage of rare diseases, which are defined in research communities as ...
متن کاملStructural basis for hydroxycholesterols as natural ligands of orphan nuclear receptor RORgamma.
The retinoic acid-related orphan receptor gamma (RORgamma) has important roles in development and metabolic homeostasis. Although the biological functions of RORgamma have been studied extensively, no ligands for RORgamma have been identified, and no structure of RORgamma has been reported. In this study, we showed that hydroxycholesterols promote the recruitment of coactivators by RORgamma usi...
متن کاملPharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007–13) and prospective (2014–18) MIDAS sales data analysis
BACKGROUND Health Canada has defined rare diseases as life-threatening, seriously debilitating, or serious chronic conditions affecting a very small number of patients (~1 in 2,000 persons). An estimated 9 % of Canadians suffer from a rare disease. Drugs treating rare diseases (DRDs) are also known as orphan drugs. While Canada is currently developing an orphan drug framework, in the United Sta...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2013